These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2476606)

  • 1. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
    Hagemeijer F; Brand HJ; Roth W
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):302-10. PubMed ID: 2476606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
    Hagemeijer F; Roth W; Brand HJ
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
    Baumann G; Ningel K; Permanetter B
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
    Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
    Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    Hagemeijer F
    Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent.
    Renard M; Walter M; Liebens I; Dresse A; Bernard R
    Chest; 1988 Jun; 93(6):1159-64. PubMed ID: 3371093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses.
    Walter M; Liebens I; Goethals H; Renard M; Dresse A; Bernard R
    Br J Clin Pharmacol; 1988 Mar; 25(3):323-9. PubMed ID: 3282531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
    Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
    Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
    Hauf GF; Grom E; Jähnchen E; Roskamm H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function.
    Permanetter B; Sebening H; Hartmann F; Klein G
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S36-40. PubMed ID: 2478790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy.
    Permanetter B; Sebening H; Hartmann F; Baumann G; Lutilsky L
    J Cardiovasc Pharmacol; 1989 Dec; 14(6):803-9. PubMed ID: 2481765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Hagemeijer F; Brand HJ; van Mechelen R
    Am J Cardiol; 1989 Mar; 63(9):571-6. PubMed ID: 2919561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of UD-CG 212 CL, a metabolite of pimobendan, in anaesthetized pigs.
    Verdouw PD; Levinsky L; Duncker DJ; Rutteman AM; Saxena PR
    Eur J Pharmacol; 1987 Jun; 137(2-3):219-26. PubMed ID: 2886352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study.
    Erlemeier HH; Kupper W; Bleifeld W
    Eur Heart J; 1991 Aug; 12(8):889-99. PubMed ID: 1915427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig.
    Duncker DJ; Hartog JM; Levinsky L; Verdouw PD
    Br J Pharmacol; 1987 Jul; 91(3):609-15. PubMed ID: 3607369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
    Kato K
    Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
    Lubsen J; Just H; Hjalmarsson AC; La Framboise D; Remme WJ; Heinrich-Nols J; Dumont JM; Seed P
    Heart; 1996 Sep; 76(3):223-31. PubMed ID: 8868980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.